Cogent Biosciences's book value per share for the quarter that ended in Mar. 2026 was $3.18.
During the past 12 months, Cogent Biosciences's average Book Value Per Share Growth Rate was 226.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Cogent Biosciences was 7.70% per year. The lowest was -28.40% per year. And the median was -15.70% per year.
Cogent Biosciences's current price is $40.01. Its book value per share for the quarter that ended in Mar. 2026 was $3.18. Hence, today's PB Ratio of Cogent Biosciences is 12.59.
During the past 11 years, the highest P/B Ratio of Cogent Biosciences was 13.16. The lowest was 0.31. And the median was 2.69.
Warning Sign:
Cogent Biosciences Inc stock PB Ratio (=12.4) is close to 10-year high of 13.16.
Cogent Biosciences (NAS:COGT) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Cogent Biosciences Book Value per Share Related Terms
Cogent Biosciences Book Value per Share Historical Data
* Premium members only.
The historical data trend for Cogent Biosciences's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COGT vs SRRK, CGON, LGND: Book Value per Share Comparison
For the Biotechnology subindustry, Cogent Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (COGT) has a Book Value per Share of $3.18 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Cogent Biosciences and its competitors.
Is Cogent Biosciences' Book Value per Share too high?
Cogent Biosciences' current Book Value per Share is $3.18. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Book Value per Share compare to SRRK and CGON?
Cogent Biosciences' Book Value per Share of $3.18 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Cogent Biosciences and its competitors. Cogent Biosciences's current Book Value per Share is $3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Book Value per Share of $3.18. The current Book Value per Share is $3.18. Cogent Biosciences' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Book Value per Share is $3.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score
Get the complete analysis for COGT
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
